8 Stocks Beating Wall Street's Q2 Targets
AI remains the defining theme for the second quarter earnings season.
Pmv Pharmaceuticals Inc. (PMVP)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Tang Capital Management Kevin C. Tang | 4,245,085 | $5,688,414 | 0.26% | |
| 2. | Sio Capital Michael Castor | 2,634,137 | $3,529,744 | -15% | 0.58% |
| 3. | Euclidean Capital Jim Simons | 2,627,643 | $3,521,042 | 0.8% | |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 2,360,000 | $3,162,400 | +27% | 0% |
| 5. | Eversept Partners Kamran Moghtaderi | 1,890,904 | $2,533,811 | -20% | 0.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.00 | 55,555 | $999,990.00 | 55,555 | 2020-09-25 | Filing | |
| $18.00 | 55,555 | $999,990.00 | 55,555 | 2020-09-25 | Filing | |
| $18.00 | 950,000 | $17,100,000.00 | 950,000 | 2020-09-25 | Filing | |
| $18.00 | 475,000 | $8,550,000.00 | 475,000 | 2020-09-25 | Filing | |
| $18.00 | 475,000 | $8,550,000.00 | 475,000 | 2020-09-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.52 | 1,000,000 | $1,520,000.00 | 4,975,291 | 2025-10-23 | Filing | |
| $1.80 | 500,000 | $900,000.00 | 5,975,291 | 2025-09-10 | Filing | |
| $1.06 | 23,151 | $24,651.18 | 98,695 | 2025-07-01 | Filing | |
| $1.06 | 33,065 | $35,197.69 | 89,959 | 2025-07-01 | Filing | |
| $1.06 | 28,249 | $30,076.71 | 60,146 | 2025-07-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,330,000 | $7,142,200 | 4.06% | |
| 2. | 2,012,020 | $2,696,107 | 0% | |
| 3. | 1,959,579 | $2,625,836 | 0.11% | |
| 4. | 919,818 | $1,232,556 | 0% | |
| 5. | 473,158 | $634,624 | 0% |
News See All
Why PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial Activity
TheFly reported on May 13 that Oppenheimer reduced its price target on PMVP from $6 to $5 while maintaining an Outperform rating after the company’s latest quarterly update.
10 Popular Penny Stocks on Robinhood to Watch in 2026
Penny stocks remain one of the market’s most debated investment areas, offering the potential for enormous gains while carrying equally significant risks.
15 Most Shorted Stocks Right Now
The stock market has been volatile in the past few months as soaring inflation and rising rates combine to create an uncertain business environment in which growth stocks have taken a beating.
10 Most Shorted Stocks in September
In the past two years, short squeezes have become a hot and a controversial topic on Wall Street.
10 Most Shorted Stocks to Watch in July
According to data shared by S3 Partners, short sellers increased their bets against the US stock market by $20 billion in June 2022.
Analysts Just Increased Price Targets of These 5 Stocks
In this article, we discuss 5 stocks that analysts just increased the price targets of.
5 Best Biotech and AI Stocks To Buy According To Billionaire Jim Simons
In this article, we discuss 5 stock picks of Jim Simons’ Euclidean Capital.
Do Hedge Funds Love PMV Pharmaceuticals, Inc. (PMVP)?
We at Insider Monkey have gone over 867 13F filings that hedge funds and prominent investors are required to file by the SEC.
5 Pharmaceutical Stocks to Buy According to Jim Simons’ Euclidean Capital
Below is the list of 5 pharmaceutical stocks to buy according to Jim Simons’ Euclidean Capital.
Hedge Fund Resource Center